Details

Autor(en) / Beteiligte

• Jarrahi, Abbas
• Ahluwalia, Meenakshi
• Khodadadi, Hesam
• da Silva Lopes Salles, Evila
• Kolhe, Ravindra
• Hess, David C
• Vale, Fernando
• Kumar, Manish
• Baban, Babak
• Vaibhav, Kumar
• Dhandapani, Krishnan M

Titel

Neurological consequences of COVID-19: what have we learned and where do we go from here?

Ist Teil von

• Journal of neuroinflammation, 2020-09, Vol.17 (1), p.286-286, Article 286

Ort / Verlag

England: BioMed Central Ltd

Erscheinungsjahr

2020

Link zum Volltext

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• The coronavirus disease-19 (COVID-19) pandemic is an unprecedented worldwide health crisis. COVID-19 is caused by SARS-CoV-2, a highly infectious pathogen that is genetically similar to SARS-CoV. Similar to other recent coronavirus outbreaks, including SARS and MERS, SARS-CoV-2 infected patients typically present with fever, dry cough, fatigue, and lower respiratory system dysfunction, including high rates of pneumonia and acute respiratory distress syndrome (ARDS); however, a rapidly accumulating set of clinical studies revealed atypical symptoms of COVID-19 that involve neurological signs, including headaches, anosmia, nausea, dysgeusia, damage to respiratory centers, and cerebral infarction. These unexpected findings may provide important clues regarding the pathological sequela of SARS-CoV-2 infection. Moreover, no efficacious therapies or vaccines are currently available, complicating the clinical management of COVID-19 patients and emphasizing the public health need for controlled, hypothesis-driven experimental studies to provide a framework for therapeutic development. In this mini-review, we summarize the current body of literature regarding the central nervous system (CNS) effects of SARS-CoV-2 and discuss several potential targets for therapeutic development to reduce neurological consequences in COVID-19 patients.